Research on thalidomide in solid tumors, hematologic malignancies, and supportive care.
Hussein
M A
MA
Cleveland Clinic Cancer Center, Cleveland, Ohio, USA.
D000975:Antioxidants / Q000494:pharmacology; D004249:DNA Damage; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic; D010587:Phagocytosis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013792:Thalidomide / Q000494:pharmacology* / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000494:pharmacology
D000975:Antioxidants; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide